This study is looking at how Guselkumab, an FDA-approved medication for psoriasis, affects the immune cells in scalp psoriasis lesions. Researchers want to understand how this medication works at a cellular level. You might be able to join if you are 18 or older and have moderate to severe scalp psoriasis (a Psoriasis Scalp Severity Index, or PSSI, score of 12 or higher). You cannot join if you are pregnant, breastfeeding, have a severe immune problem, an active serious infection like tuberculosis, or cancer. The study will measure changes in your scalp psoriasis severity after about 9 months of Guselkumab treatment. The current recruitment status is unclear, and the study plans to enroll 10 participants.

Study design

This is an open-label study, meaning you and the researchers will know you are receiving Guselkumab. It is a single-arm study, so all 10 participants will receive the same treatment.

What's involved

You will receive Guselkumab treatment for approximately 9 months. Biopsy samples will be collected at baseline and at 9 months.

Compensation

Not stated in the trial record.

Follow-up

Your scalp psoriasis severity will be measured at baseline and again at 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.